CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Senores Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Senores Pharmaceuticals Ltd
Phone: +91 7929999857p:+91 7929999857 AHMEDABAD, 380054  India Ticker: SENORESSENORES
Business Summary
Senores Pharmaceuticals Limited is an India-based pharmaceutical company. The Company manufactures products of international quality to cater to the increasing new age demands of the global healthcare industry. The Company's products include Amphetamine Sulfate Tablets USP, 5 mg and 10 mg; Hydroxychloroquine Sulfate Tablets USP, 200 mg; Ketoconazole Tablets USP, 200 mg; Chlorzoxazone Tablets USP, 250 mg; 5Chlorzoxazone Tablets USP, 500 mg; Ketorolac Tromethamine Tablets USP, 10 mg; Diclofenac Potassium Tablets USP, 25 mg; Diclofenac Potassium Tablets USP, 50 mg, and others. It supplies affordable APIs to generic formulations manufacturers. Its product API include Anastrozole, Aripiprazole, Benfotiamine, Clomiphene Citrate, Desloratadine, Desvenlafaxine Succinate, Fluoxetine Hydrochloride, and others. Its domestic portfolio includes Azithromycin for Injection; Meropenem Injection; Ferric Carboxymaltose Injection; Meropenem and Sulbactam for Injection, and others.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20243/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Non-Independent Chairman of the Board Sanjay S.Majmudar 61 2/10/2024 2/10/2024
Chief Financial Officer, Whole Time Director Deval R.Shah 60 5/1/2024 1/1/2020
Chief Operating Officer, Whole Time Director Chetan B.Shah 58 11/10/2023 11/10/2023
10 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 46,053,588 (As of 12/30/2024)
Stock Exchange: NSE


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, January 20, 2025